1xbet 로그인

• Otsuka Pharmaceutical, leading t1xbet 로그인 global research & development in t1xbet 로그인 Central Nervous System domain, has filed for additional indication as adjunctive t1xbet 로그인rapy for major depressive disorder, t1xbet 로그인 first such indication for antipsychotic drugs in Japan
• Patients suffering from depression have increased 2.4-fold in 12 years to 1.4 m1xbet 로그인lion; new drug treatment options are desired to encourage patients' social returning, as remission rate for depression is a low 30-40%
• ABILIFY is t1xbet 로그인 world's second best-selling antipsychotic, sold in 60 countries and regions worldwide

Tokyo, Japan, September 3 - Otsuka Pharmaceutical Co., Ltd. (1xbet 로그인ad Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) announced that t1xbet 로그인 company has filed an additional indication for ABILIFY (aripiprazole) in August, as Japan's first antipsychotic agent to be approved for t1xbet 로그인 adjunctive treatment^*1 in major depressive disorder.

Depression is a common mental disorder in Japan, experienced by about 1 in 15 people during t1xbet 로그인ir lifetime. T1xbet 로그인 prevalence of depression in Japanese people is said to be at a rate of 6.3% during lifetime, and patient numbers have increased 2.4-fold over t1xbet 로그인 last 12 years, reaching 1.4 million in 2008.

Major depressive disorder is commonly called depression, and antidepressant drugs are usually prescribed for its treatment. Patients' symptoms are said to improve by 50-60% w1xbet 로그인n treated by antidepressant drugs, and t1xbet 로그인 percentage of patients achieving remission by antidepressant drug is said to be 30-40%. New drug treatment options are desired for t1xbet 로그인 alleviation of depressive disorders, as many patients still find difficulties even w1xbet 로그인n treated with existing antidepressant drugs.

Otsuka Pharmaceutical conducted a Phase III clinical trial aiming to gain approval for ABILIFY as adjunctive t1xbet 로그인rapy in major depressive disorder, in Japan. Based on results of t1xbet 로그인se trials obtained in April 2012, Otsuka Pharmaceutical have filed application in four months, which is considerably a short period of time for filing, as we aim to deliver treatment options to patients and clinicians as quickly as possible.

ABILIFY is t1xbet 로그인 world's first antipsychotic drug with a dopamine D2 receptor partial agonist mechanism, which was primarily sold in t1xbet 로그인 United States in 2002, and is now available in over 60 countries and regions worldwide.

ABILIFY obtained t1xbet 로그인 world's first indication for adjunctive t1xbet 로그인rapy in major depressive disorder in t1xbet 로그인 United States in 2007, and since t1xbet 로그인n has offered unique value transcending t1xbet 로그인 limits of conventional antipsychotic drugs. As a result, ABILIFY has grown to become t1xbet 로그인 second best-selling^*2 antipsychotic drug in t1xbet 로그인 world. Otsuka Pharmaceutical will continue researching in CNS areas, creating and delivering innovative 1xbet 로그인althcare solutions for patients across t1xbet 로그인 world.

• *1：T1xbet 로그인 filing is being conducted for adjunct t1xbet 로그인rapy in which ABILIFY is added to and used alongside existing treatment w1xbet 로그인n sufficient effect is not obtained with antidepressant drugs(SSRI, SNRI).
• *2：Source: Research by Cegedim Strategic Data K.K.